Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials
详细信息 查看全文
- 作者：Sven Mensing ; Doerthe Eckert ; Shringi Sharma ; Akshanth R. Polepally ; Amit Khatri ; Thomas J. Podsadecki ; Walid M. Awni ; Rajeev M. Menon and Sandeep Dutta
- 刊名：British Journal of Clinical Pharmacology
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：83
- 期：3
- 页码：527-539
- 全文大小：888K
- ISSN：1365-2125
文摘
The aim of the current study was to characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir–ritonavir and dasabuvir) and adjunctive ribavirin, and estimate covariate effects in a broad spectrum of subjects with hepatitis C virus (HCV) genotype 1 infection.